-
Such ailments have always been Genzyme's (nasdaq: GENZ - news - people ) specialty.
FORBES: Genzyme Inks Deal With Isis On Cholesterol Drug
-
Genzyme (nasdaq: GENZ - news - people ) has proved skeptics wrong in the past.
FORBES: Can Genzyme Defy Skeptics Again?
-
The deal will be accretive to Genzyme's (nasdaq: GENZ - news - people ) GAAP earnings after 2004.
FORBES: Genzyme To Buy SangStat For $600 Million
-
Genzyme ( GENZ - news - people ).
FORBES: Strategies
-
"Ironically, you have an antibiotic-induced disease being treated with more antibiotics, " says David Davidson, medical director at Genzyme (nasdaq: GENZ - news - people ).
FORBES: On The Cover/Top Stories
-
IBM's Web focus also exploits the timely appeal that software-as-a-service has to IT managers' wallets in the midst of the current economic downturn, says IDC Research Analyst Frank Genz.
FORBES: Enterprise
-
Genzyme (nasdaq: GENZ - news - people ), which is co-marketing the drug in a 50-50 joint venture, has to do a good job selling it.
FORBES: Magazine Article
-
Making matters worse, the same panel said that the data for a rival drug for Fabry made by the company's Cambridge, Mass-based neighbor Genzyme (nasdaq: GENZ - news - people ) supported its effectiveness.
FORBES: Magazine Article
-
As Genzyme (nasdaq: GENZ - news - people ) did in its early days, BioMarin (nasdaq: BMRN - news - people ) focuses on drugs for rare genetic diseases, usually those in which one enzyme is defective.
FORBES: BioMarin Follows Genzyme's Playbook
-
Some big-selling biotech drugs are proteins themselves: Amgen's (nyse: AMGN - news - people) Epogen, Immunex's (nasdaq: IMNX - news - people) Enbrel and Genzyme's (nasdaq: GENZ - news - people) Cerezyme, for example.
FORBES: Rosetta Inpharmatics Riding The Gene Wave
-
Moreover, drugs for such "orphan" diseases can be priced at tens of thousands of dollars a year or more--a fact that has been proven again and again by biotechs like Genzyme (nasdaq: GENZ - news - people ) that focus on rare diseases.
FORBES: Cholesterol Comeback
-
Biotech has also led the market this year, and this month Collins is adding Amgen (nasdaq: AMGN - news - people ) and Genzyme General (nasdaq: GENZ - news - people ) to his portfolio--both of which are trading near their 52-week highs.
FORBES: Magazine Article